Test Price
2,800 AED✅ Home Collection Available
DYNC1H1 Gene Intellectual Disability, Autosomal Dominant 13 (MRD13) Genetic Test in UAE | 2800 AED
Executive Summary & Core Metrics
99.9% Diagnostic Accuracy via ISO 9001:2015 Certified Processing
- Diagnostic Sensitivity: 99.9% through accredited next-generation sequencing (NGS) analysis for pathogenic variants in the DYNC1H1 gene.
- Premium Logistics: VIP mobile phlebotomy and temperature-controlled cold-chain home collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Post-test telephonic session with a consultant medical geneticist to interpret results and advise on familial implications.
- Insurance Verification: Direct coverage confirmation via WhatsApp at +971 54 548 8731.
Test Overview & Methodology
The DYNC1H1 gene test employs Next-Generation Sequencing (NGS) to identify pathogenic variants associated with autosomal dominant intellectual disability type 13 (MRD13). This targeted single-gene analysis provides definitive diagnosis, enables accurate prognosis, and informs reproductive planning for affected individuals and their families.
| Feature | Our Test (DYNC1H1 NGS) | Closest Alternative (Whole Exome Sequencing) |
|---|---|---|
| Target Precision | Full coding region of DYNC1H1 – single-gene depth >200x | Genome-wide, DYNC1H1 coverage variable |
| Turnaround Time | 3–4 weeks | 8–12 weeks |
| Variant Interpretation | ACMG-guided, phenotype-specific | Broader, may require additional follow-up |
| Cost in UAE | 2800 AED | Estimated 4500–6000 AED |
Physician Insight & Safety Protocols
Advisory Precautions
Critical Safety Information
- Medication Advisory: Do not discontinue any prescribed medication or therapy without direct instruction from your managing physician.
- Clinical Context: A positive result alone does not confirm a diagnosis; results must be correlated with clinical features, developmental history, and family pedigree.
- Emergency Red Flags: Seek immediate medical attention if the patient experiences a seizure lasting more than 5 minutes, sudden loss of developmental milestones, an unresponsive state, or acute encephalopathy.
Exclusion Criteria & Contraindications
When This Test Is Not Appropriate
- Sample Collection Exclusion: Active severe bleeding disorder (e.g., hemophilia without factor replacement) or inability to obtain a peripheral blood sample due to severe burns or venous access failure.
- Indication Caution: This test is not a screening tool for asymptomatic minors without a known familial mutation; pre-test genetic counselling is mandatory.
- Variant Interpretation: A variant of uncertain significance (VUS) does not constitute a clinical diagnosis and should not guide treatment decisions without further investigation.
Patient FAQ & Clinical Guidance
1. What is the DYNC1H1 gene test and why is it done?
The DYNC1H1 NGS test detects mutations in the DYNC1H1 gene causing autosomal dominant intellectual disability type 13 (MRD13). It is indicated when a child or adult presents with global developmental delay, intellectual disability, microcephaly, or cortical malformations suggestive of a DYNC1H1-related disorder. A positive result confirms the genetic cause, enables predictive testing in at-risk relatives, and guides reproductive options.
2. How is the sample collected and what preparation is required?
A simple blood draw (2–5 mL in an EDTA tube) or a dried blood spot on an FTA card is required. No fasting or medication changes are needed. Our VIP mobile phlebotomy team visits your home, office, or hotel between 8 AM and 11 PM with full cold-chain compliance. Please ensure the requisition form includes the patient’s detailed clinical history and a copy of the genetic counselling pedigree chart.
3. What do the results mean and how will I receive them?
Results are reported as Pathogenic, Likely Pathogenic, Variant of Uncertain Significance (VUS), Likely Benign, or Benign, always with clinical correlation advice. Within 3–4 weeks your confidential report is delivered via secure email, followed by a telephonic session with a Consultant Medical Geneticist who explains the findings, implications for family members, and next steps. All data handling adheres to UAE Personal Data Protection Law (PDPL) and health data regulations, guaranteeing your privacy.
4. Who should consider taking this test?
This test is recommended for individuals with unexplained global developmental delay, intellectual disability, or specific brain malformations (e.g., pachygyria or polymicrogyria) suggestive of DYNC1H1 involvement. It is also appropriate for adults with a family history of autosomal dominant intellectual disability who desire reproductive planning or predictive testing.
UAE Regulatory & Data Privacy Adherence
Regulatory Compliance & Data Protection Framework
- Personal Data Protection: Your genetic information and clinical data are processed and stored in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL).
- Health Data Security: All health information is handled according to Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring encrypted transmission and secure access controls.
- Medical Liability: Clinical procedures and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability, safeguarding your rights throughout the testing process.
- Accreditation: The laboratory holds ISO 9001:2015 certification (Certificate: INT/EGQ/2509DA/3139), ensuring rigorous quality management systems.
Clinical & Logistical Metadata
| Test Name | DYNC1H1 Gene Intellectual Disability, Autosomal Dominant 13 (MRD13) Genetic Test |
| Price (AED) | 2800 AED |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Whole Blood (EDTA Tube) or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Single-Gene Panel, Full Coding Region, >200x Depth |
| ICD-10-CM Code | F78, Q04.8 |
| LOINC Code | 94219-1 |
| DHA Facility License & Laboratory Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians